Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson’s Disease
Tafreshi, Ali , Beach, Thomas G. , Tashiro, Stephanie, Wang, Charles , Dashtipour, Khashayar , Adler, Charles H. , Chen, Xin , Serrano, Geidy E. , Tashiro, Stephanie

Mayo Clinic

Brain Sciences | June 28, 2017 | Volume: 7 | Issue: 7 | Pages: 74

10.3390/brainsci7070074 | PMID 28653979 Get It

Objective: To determine and compare DNA methylation patterns between patients with Parkinson’s disease (PD) and age- and sex-similar matched non-PD controls. Background: Epigenetic regulation is one of the major mechanisms for an organism to respond to the environment through changes in gene expression and has been implicated in numerous disease processes. We would like to examine epigenetic modification patterns that may predispose or protect against PD. Methods: Frozen tissue samples of the human cerebral cortex from 12 PD patients and 12 subjects without PD pathology were obtained. Genome-wide DNA methylation profiling was performed using the Illumina HumanMethylation450 BeadChip array. Differential methylation was defined as a mean methylation level difference (delta β) of at least 0.20 (Δβ ≥ 0.20). Methylation regions with an absolute delta β value ≥ 0.20 were selected for further gene function studies. Results: We identified 2795 differentially methylated CpG sites in the frontal cortex of PD cases with a detection p-value of ≤ 0.01 and 328 differentially methylated CpG sites with a detection p-value of ≤ 0.001. A pattern of robust hypermethylation of synphilin-1, α-synuclein-interacting protein (SNCAIP) gene was found in the brain of PD cases (p = 4.93 × 10−7 and delta β = 0.60). Conclusion: Our findings support a link between SNCAIP methylation and PD risk. Hypomethylation of SNCAIP may function to protect against PD. The current results may suggest that the methylation status of SNCAIP could be useful as a marker in PD diagnosis and treatment and warrants further investigation.
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy‐organomegaly‐endocrinopathy‐monoclonal protein‐skin changes and chronic inflammatory demyelinating polyradiculoneuropathy
Wang, Wei , Litchy, William J. , Mauermann, Michelle L. , Dyck, P. James B. , Mandrekar, Jay , Klein, Christopher J. , Dispenzieri, Angela , Klein, Christopher J , Mauermann, Michelle L

Mayo Clinic

Muscle & Nerve | June 24, 2017 | Volume: 57 | Issue: 1 | Pages: No page available

10.1002/mus.25731 | PMID 28646568 Get It

ABSTRACTIntroduction: In polyradiculoneuropathy‐organomegaly‐endocrinopathy‐monoclonal protein‐skin changes (POEMS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), limb nerve conduction studies (NCSs) are limited in identifying demyelination and in detecting treatment effects in severely affected patients. Blink R1 latency may improve these assessments. Methods: POEMS and CIDP patients who had undergone NCS and blink reflex were identified. Correlations among R1 latency, limb NCS, and neuropathy impairment scores (NIS) were compared. Results: Among 182 patients (124 POEMS, 58 CIDP) who were identified, R1 prolongation (>13 ms) occurred in 64.3% (65.3% POEMS, 62.1% CIDP). R1 prolongation correlated with more severely affected NCS in both POEMS (ulnar CMAP 2.6 mV vs. 4.5 mV, P = 0.001) and CIDP (2.0 mV vs. 6.1 mV, P < 0.001). In severely affected patients (ulnar CMAP ≤0.5 mV [10%:18/182]), R1 (>13 ms) helped establish demyelination. In 31 patients (16 POEMS, 15 CIDP), the R1 latency changes were concordant with NIS changes in 94% of patients with POEMS and 60% of patients with CIDP. Discussion: Blink R1 latencies are valuable in defining demyelination and detecting improvement in severely affected POEMS and CIDP patients. Muscle Nerve 57: E8–E13, 2018
Flipped Classrooms in Graduate Medical Education: A National Survey of Residency Program Directors
Wittich, Christopher M. , Agrawal, Anoop , Wang, Amy T. , Halvorsen, Andrew J. , Mandrekar, Jayawant N. , Chaudhry, Saima , Dupras, Denise M. , Beckman, Thomas J. , Oxentenko, Amy S.

Mayo Clinic

Academic Medicine | June 21, 2017 | Volume: 93 | Issue: 3 | Pages: 471-477

10.1097/acm.0000000000001776 | PMID 28640030 Get It

Purpose To begin to quantify and understand the use of the flipped classroom (FC)—a progressive, effective, curricular model—in internal medicine (IM) education in relation to residency program and program director (PD) characteristics. Method The authors conducted a survey that included the Flipped Classroom Perception Instrument (FCPI) in 2015 regarding programs’ use and PDs’ perceptions of the FC model. Results Among the 368 IM residency programs, PDs at 227 (61.7%) responded to the survey and 206 (56.0%) completed the FCPI. Regarding how often programs used the FC model, 34 of the 206 PDs (16.5%) reported “never”; 44 (21.4%) reported “very rarely”; another 44 (21.4%) reported “somewhat rarely”; 59 (28.6%) reported “sometimes”; 16 (7.8%) reported “somewhat often”; and 9 (4.4%) reported “very often.” The mean FCPI score (standard deviation [SD]) for the in-class application factor (4.11 [0.68]) was higher (i.e., more favorable) than for the preclass activity factor (3.94 [0.65]) ( P < .001). FC perceptions (mean [SD]) were higher among younger PDs (≤ 50 years, 4.12 [0.62]; > 50 years, 3.94 [0.61]; P = .04) and women compared with men (4.28 [0.56] vs. 3.91 [0.62]; P < .001). PDs with better perceptions of FCs had higher odds of using FCs (odds ratio, 4.768; P < .001). Conclusions Most IM programs use the FC model at least to some extent, and PDs prefer the interactive in-class components over the independent preclass activities. PDs who are women and younger perceived the model more favorably.
A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults
Daver, Naval , McClain, Kenneth L. , Allen, Carl E. , Otrock, Zaher K. , Rojas‐Hernandez, Cristhiam M. , Blechacz, Boris, Wang, Sa , Minkov, Milen , Jordan, Michael B. , Rosée, Paul La , Kantarjian, Hagop M. , Parikh, Sameer A. , Daver, Naval , McClain, Kenneth L , Allen, Carl E , Kantarjian, Hagop

Mayo Clinic

Cancer | June 16, 2017 | Volume: 123 | Issue: 17 | Pages: 3229-3240

10.1002/cncr.30826 | PMID 28621800 Get It

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of severe immune activation and dysregulation resulting in extreme and often life‐threatening inflammation. HLH has been well recognized in pediatric populations, and most current diagnostic and therapeutic guidelines are based on pediatric HLH. Recently there has been recognition of HLH in adults, especially secondary to immune deregulation by an underlying rheumatologic, infectious, or malignant condition. This review is focused on malignancy‐associated HLH (M‐HLH), in which possible mechanisms of pathogenesis include severe inflammation, persistent antigen stimulation by the tumor cells, and loss of immune homeostasis because of chemotherapy, hematopoietic stem cell transplantation, or infection. Previously considered rare, M‐HLH may occur in up to 1% of patients with hematologic malignancies. M‐HLH is often missed or diagnosed late in most published studies, and it has been associated with a poor median survival of less than 2 months. Identification of the clinical and laboratory features specific to M‐HLH in adults may allow early detection, consultation with HLH experts, and intervention. Improved management of adult M‐HLH with optimal combinations of T‐lympholytic and immunosuppressive agents and the incorporation of novel agents based on the pediatric experience hopefully will improve outcomes in adults with M‐HLH. Cancer 2017;123:3229‐40. © 2017 American Cancer Society.
Loss of FAM46C Promotes Cell Survival in Myeloma
Zhu, Yuan Xiao , Shi, Chang-Xin, Bruins, Laura A., Jedlowski, Patrick , Wang, Xuewei , Luo, Moulun , Ahmann, Jonathan M., Braggio, Esteban , Stewart, A. Keith, Kortüm, K. Martin , Braggio, Esteban

Mayo Clinic

Cancer Research | June 15, 2017 | Volume: 77 | Issue: 16 | Pages: 4317-4327

10.1158/0008-5472.can-16-3011 | PMID 28619709 Get It

Abstract FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis. Cancer Res; 77(16); 4317–27. ©2017 AACR.
The regulatory 1α subunit of protein kinase A modulates renal cystogenesis
Ye, Hong , Constans, Megan, Sussman, Caroline R. , Irazabal, María V. , Harris, Peter C. , Kirschner, Lawrence S. , Torres, Vicente E. , Constans, Megan M, Ye, Hong, Wang, Xiaofang , Chebib, Fouad T. , Young, William F. , Harris, Peter C , Torres, Vicente E , Irazabal, Maria V , Sussman, Caroline R.

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 14, 2017 | Volume: 313 | Issue: 3 | Pages: F677-F686

10.1152/ajprenal.00119.2017 | PMID 28615245 Get It

The failure of the polycystins (PCs) to function in primary cilia is thought to be responsible for autosomal dominant polycystic kidney disease (ADPKD). Primary cilia integrate multiple cellular signaling pathways, including calcium, cAMP, Wnt, and Hedgehog, which control cell proliferation and differentiation. It has been proposed that mutated PCs result in reduced intracellular calcium, which in turn upregulates cAMP, protein kinase A (PKA) signaling, and subsequently other proliferative signaling pathways. However, the role of PKA in ADPKD has not been directly ascertained in vivo, although the expression of the main regulatory subunit of PKA in cilia and other compartments (PKA-RIα, encoded by PRKAR1A) is increased in a mouse model orthologous to ADPKD. Therefore, we generated a kidney-specific knockout of Prkar1a to examine the consequences of constitutive upregulation of PKA on wild-type and Pkd1 hypomorphic ( Pkd1 RC ) backgrounds. Kidney-specific loss of Prkar1a induced renal cystic disease and markedly aggravated cystogenesis in the Pkd1 RC models. In both settings, it was accompanied by upregulation of Src, Ras, MAPK/ERK, mTOR, CREB, STAT3, Pax2 and Wnt signaling. On the other hand, Gli3 repressor activity was enhanced, possibly contributing to hydronephrosis and impaired glomerulogenesis in some animals. To assess the relevance of these observations in humans we looked for and found evidence for kidney and liver cystic phenotypes in the Carney complex, a tumoral syndrome caused by mutations in PRKAR1A. These observations expand our understanding of the pathogenesis of ADPKD and demonstrate the importance of PRKAR1A highlighting PKA as a therapeutic target in ADPKD.
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Casuscelli, Jozefina , Gundem, Gunes , Wang, Lu , Zabor, Emily C. , Drill, Esther , Wang, Patricia I., Nanjangud, Gouri J. , Redzematovic, Almedina, Nargund, Amrita M. , Manley, Brandon J. , Arcila, Maria E. , Donin, Nicholas M. , Cheville, John C. , Thompson, R. Houston, Pantuck, Allan J., Russo, Paul , Cheng, Emily H. , Lee, William , Tickoo, Satish K. , Ostrovnaya, Irina , Creighton, Chad J. , Papaemmanuil, Elli , Seshan, Venkatraman , Hsieh, James J. , Weinhold, Nils , Hakimi, A Ari , Manley, Brandon J

Mayo Clinic

JCI Insight | June 14, 2017 | Volume: 2 | Issue: 12 | Pages: No page available

10.1172/jci.insight.92688 | PMID 28614790 Get It

Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%–10% metastatic incidence. Since extensive chromosomal losses can generate proteotoxic stress and compromise cellular proliferation, it is intriguing how chRCC, a tumor with extensive chromosome losses and a low number of somatic mutations, can develop lethal metastases. Genomic features distinguishing metastatic from nonmetastatic chRCC are unknown. An integrated approach, including whole-genome sequencing (WGS), targeted ultradeep cancer gene sequencing, and chromosome analyses (FACETS, OncoScan, and FISH), was performed on 79 chRCC patients including 38 metastatic (M-chRCC) cases. We demonstrate that TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC. Reconstruction of the subclonal composition of paired primary-metastatic chRCC tumors supports the role of TP53 , PTEN , and ICD in metastatic evolution. Finally, the presence of these 3 genomic features in primary tumors of both The Cancer Genome Atlas kidney chromophobe (KICH) ( n = 64) and M-chRCC ( n = 35) cohorts was associated with worse survival. In summary, our study provides genomic insights into the metastatic progression of chRCC and identifies TP53 mutations, PTEN mutations, and ICD as high-risk features.
Current Understanding and Management of Splenic Steal Syndrome after Liver Transplant: A Systematic Review
Tsui, Brian , Li, Chaolun , Kapoor, Baljendra , Moon, Eunice , Quintini, Cristiano , Wang, Weiping

Mayo Clinic

Digestive Disease Interventions | June 8, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0037-1603724 Get It

Added Value of Covered Stents in Transjugular Intrahepatic Portosystemic Shunt: A Large Single-Center Experience
Wang, Weiping , Shah, Chintan , Sands, Mark, Bullen, Jennifer , Bayona, Pilar, Carey, William, Kapoor, Baljendra , Gupta, Amar C. , Remer, Erick M.

Mayo Clinic

Digestive Disease Interventions | June 8, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0037-1603696 Get It